Afatinib as first-line treatment in Asian patients with EGFR mutation-positive NSCLC: A narrative review of real-world evidence

• Main Authors: Lu, Shun, Shih, Jin-Yuan, Jang, Tae-Won, Liam, Chong-Kin, Yu, Yongfeng
• 格式: Article
• 出版: Springer 2021
• 主题: RM Therapeutics. Pharmacology
• 在线阅读: http://eprints.um.edu.my/26835/

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC). EGFR mutations are relatively common in Asian patients with NSCLC, and there is an increas...